Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Nephro-Urology Monthly
  4. Articles

  5. Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-Year-Old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report
  6. Scopus by Title (Ref)

Nephro-Urology Monthly

Home
Current IssueAll IssuesIn PressSearchAccepted Manuscripts
Instructions
Journal InformationBoards and CommitteesIndexing and Listing SourcesPublication Ethics and Malpractice StatementSupportReviewer and AE Registration FormContact UsJournal MetricsOpen Peer Review (OPR)
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Unexpected hypereosinophilia after Sinopharm vaccination: a case report

- Dalfardi B. , et al.

2. Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report

- Javadian P. , et al.

3. COVID-19 vaccine-associated vasculitis: A systematic review

- Abuhammad A. , et al.

4. ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

- Thammathiwat T. , et al.

5. ANCA-associated glomerulonephritis and lupus nephritis following COVID-19 vaccination: a case report and literature review

- Campos M.A.G. , et al.

HomeInstructionsAPC

Articles

  • Current Issue
  • All Issues
  • In Press
  • Search
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Boards and Committees
  • Indexing and Listing Sources
  • Publication Ethics and Malpractice Statement
  • Support
  • Reviewer and AE Registration Form
  • Contact Us
  • Journal Metrics
  • Open Peer Review (OPR)
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.